Smurfit Westrock closed Tuesday at $46.45, up 6.3% on the week — outpacing every name in its peer group and reviving a stock that lost nearly 6% over the prior month.
The relative outperformance is the week's clearest story. Closest peer IP gained 5.1% over the same period. PKG added just 3%. SON came close at 5%, but SW's 6.3% move was the sharpest of the group. That gap is worth noting heading into the October 30 earnings date, where the bar is already somewhat reset by a tough July quarter that knocked the stock down roughly 6.5% on the day.
The positioning picture is relaxed rather than charged. Short interest runs at 4.3% of the free float — modest for a packaging name — and edged up only 1.6% across the week. More telling is how much room remains in the lending pool: availability is running at roughly 599%, meaning roughly six shares are available for every one currently borrowed. That level has actually eased back from its tightest reading of the year, which was around 467% on September 2. Cost to borrow is equally unthreatening at under 0.5%, despite ticking up about 7% on the week. The short score — ORTEX's composite short-pressure measure — holds at 44.3, close to mid-range and largely unchanged across the past two weeks. Nothing in the lending market suggests bears are building a conviction position.
Options traders tell a similar, if slightly more bullish, story. The put/call ratio dropped to 0.22 on September 22 — below its 20-day average of 0.25 and more than a standard deviation below recent norms. That tilt toward calls reflects the week's price momentum rather than any defensive hedge-building ahead of earnings. The 52-week PCR range runs from 0.08 to 0.60, so the current reading sits comfortably in call-heavy territory without being extreme.
The Street is broadly constructive, and targets have been moving up. JP Morgan lifted its price target to $69 — filed just this morning — maintaining its Overweight. Morgan Stanley raised to $58 late last month, also maintaining Overweight. A cluster of other firms including RBC, Wells Fargo, and Barclays all raised targets in late July after the last quarterly print, even as JP Morgan cut its target slightly on results day before reinstating a higher figure. The mean target implied by those moves sits in the high $50s to low $60s, representing meaningful upside to the $46.45 close. The bull case centres on containerboard volume recovery, Latin American growth, and $2.4-2.5 billion in capital expenditure expected to drive operational leverage. Bears point to the 8.7% corrugated volume decline year-over-year and a lowered EBITDA guidance range of $4.9-5.1 billion — a $100 million step-down from prior projections that landed heavily in July.
On valuation, the stock trades at roughly 15.2x trailing earnings and 6.8x EV/EBITDA — the latter down about 2% over the past month, consistent with the stock recovering only part of its one-month loss. EPS momentum factor scores are genuinely strong: 84th percentile on 30-day momentum and 76th percentile over 90 days, suggesting analyst estimate revisions have been running in the right direction even as reported volumes disappointed. The dividend score ranks in the 97th percentile, though the most recent dividend history on file reflects Smurfit Kappa's pre-merger structure and should not be treated as current guidance.
Institutional holders are sizeable and largely stable. Capital Research holds 11.1% and added nearly 5.7 million shares in the period to August 31. BlackRock and Vanguard sit at 8.7% and 7.1% respectively. State Street filed a fresh 13G in August disclosing a 5.4% stake. No 13D activists are on the register. Norges Bank's 13G from February 2025 disclosed a 4.7% stake; as a passive filer it may have moved without further disclosure. The insider activity on September 10 was entirely director share awards — grant-type transactions with no cash consideration — and carries no read-through on conviction.
The October 30 print is the next concrete test. The last three comparable reporting events all produced negative first-day reactions, with July's result delivering a 6.5% decline followed by a partial five-day recovery. Whether this week's rally reflects genuine demand recovery or simply sector rotation will become clearer once management addresses corrugated volume trends and the trajectory of EBITDA guidance into year-end.
See the live data behind this article on ORTEX.
Open SW on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
